Cord blood banking is one of the most clinically significant cryopreservation tasks in modern medicine. Cord blood contains hematopoietic stem cells (HSCs) — cells that can be life-saving in the treatment of leukemia, lymphoma, anemia, and immune deficiencies. Their storage viability at –196°C is theoretically indefinite.
For cord blood banks — public institutions like the Finnish Red Cross or private service providers like Swiss Stem Cells Biotech — cryogenic infrastructure is the operational backbone.
Cord blood is collected from the umbilical cord and placenta immediately after birth. The collection window is unique — there is no second opportunity. What is not correctly cryopreserved and stored is permanently lost.
Hematopoietic stem cells in cord blood offer a clinical advantage over bone marrow stem cells: lower GvHD (Graft-versus-Host Disease) rates and more flexible HLA matching requirements. This makes cord blood particularly valuable for allogeneic transplantation.
The standard workflow for a cord blood bank:
Collection: Cord blood collected sterile after delivery (typically 60–150 ml)
Transport: Cooled (non-cryogenic) transport to the processing laboratory — within 24–48 hours
Processing: Volume reduction, erythrocyte depletion, buffy coat enrichment
Cryoprotectant: DMSO addition (typically 10% DMSO in human serum albumin)
Freezing: Controlled cooling in a controlled rate freezer
Storage: Long-term storage at –196°C in cryogenic tanks
Step 5 is cryobiologically critical. Cord blood products are stored as cryobags — not as cryovials. This has direct consequences for the choice of freezing instrument and storage tank.
The BIOFREEZE® Controlled Rate Freezer from Consarctic® is designed to handle cryobag processing. Its TC-Aktiv function automatically detects latent heat during crystallization of DMSO-containing products and triggers the compensatory cooling impulse — maximizing HSC viability after thawing.
For cord blood banks with GMP requirements, Consarctic® recommends the BIOFREEZE® SMARTLINE with integrated audit trail software. Every freezing cycle is fully documented — a prerequisite for release of clinical cord blood units.
After freezing, cord blood products in cryobags are stored at –196°C. Consarctic® recommends the BSF+ Series:
Vapor phase storage is particularly important for cord blood: it prevents cross-contamination between patient samples — a critical safety requirement for allogeneic transplantation products.
Public banks (operating under regulatory authorization, GMP standards, and national tissue laws) collect cord blood for allogeneic transplantation. They operate under ISO 20387 or equivalent national standards. Requirements include IQ/OQ-qualified equipment, calibrated monitoring, and complete batch records.
Private banks store cord blood on family request for potential autologous use. EU Tissue Directive 2004/23/EC applies, with focus on storage quality assurance rather than allogeneic release protocols.
Both models require the same cryogenic infrastructure — the differences lie in documentation and authorization requirements.
Cord blood banks may hold hundreds to thousands of units in a single facility. A single uncontrolled temperature rise — from LN₂ level drop or system failure — can irreversibly damage an entire storage group.
The Consarctic® Monitoring-System monitors all tanks continuously. For cord blood banks, it integrates into the complete quality system: continuous temperature data, immediate alarm escalation, remote access for operations management.
After processing (volume reduction, buffy coat enrichment), cord blood is mixed with DMSO and cooled in a controlled rate freezer (BIOFREEZE® BV45 or SMARTLINE) following a validated protocol. The critical phase is the freezing point, where DMSO crystallizes — the BIOFREEZE® detects and compensates for this phase automatically.
Properly cryopreserved cord blood is viable at –196°C indefinitely. Public cord blood banks report successful transplantations with units stored for more than 20 years.
Public banks collect cord blood for allogeneic transplantation (any matching patient can access the registry) and operate under regulatory authorization. Private banks store on family request for potential autologous use. Both require qualified cryogenic infrastructure.
A mid-sized public cord blood bank may store 10,000 to 50,000 units. Each unit (cryobag, approximately 20–50 ml final volume) requires tank capacity that grows with inventory. The Consarctic® BSF+ Series is modularly expandable.
Cord blood banking is not a short-term project. Institutions building cord blood inventories with potential clinical use over decades are making an infrastructure decision with consequences spanning twenty or more years.
Consarctic GmbH supports cord blood banks from planning through IQ/OQ commissioning and ongoing 24/7 operation. The Finnish Red Cross and Swiss Stem Cells Biotech are among the institutions that have made this decision with Consarctic®.